Jefferson gets prostate test patent:
This article was originally published in Clinica
Thomas Jefferson University in Philadelphia has received a US patent for a prostate cancer metastasis test. It is based on reverse transcriptase PCR and detects cells expressing prostate-specific antigen that are circulating in the blood. Such cells indicate that cancer has migrated from the prostate. Prostate cancer frequently metastasises to bones, making prostatectomy ineffective. Jefferson has licensed the test to UroCor for the US and Raggio-Italgene for Europe and Japan. UroCor is evaluating the test at eight cancer centres in the US.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.